Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells: implications for T-cell immunotherapy.
Sandhya SharmaMae WoodsNaren U MehtaTim SauerKathan S ParikhMichael Schmuck-HenneresseHuimin ZhangBirju MehtaMalcolm K BrennerHelen E HeslopCliona M RooneyPublished in: Journal for immunotherapy of cancer (2023)
Our findings suggest that naïve T cells inhibit the outgrowth of antigen-stimulated memory T cells, highlighting the profound effects of intra-T-cell subset interactions. Having overcome our inability to generate EBVSTs from many patients with lymphoma, we have introduced CD45RA depletion into three clinical trials: NCT01555892 and NCT04288726 using autologous and allogeneic EBVSTs to treat lymphoma and NCT04013802 using multivirus-specific T cells to treat viral infections after hematopoietic stem cell transplantation.
Keyphrases
- clinical trial
- diffuse large b cell lymphoma
- bone marrow
- working memory
- stem cell transplantation
- rheumatoid arthritis
- sars cov
- acute myeloid leukemia
- hiv infected
- cell therapy
- disease activity
- phase ii
- autism spectrum disorder
- stem cells
- interstitial lung disease
- open label
- double blind
- hematopoietic stem cell
- idiopathic pulmonary fibrosis
- study protocol